Multiple myeloma clinical trial update that highlights a company's late-stage development milestone and previews implications for patients and clinicians.
Key Takeaways
- We are open to conversations with prospective partners and investors who share our vision
- Innovent Biologics has dosed the first patient in TriadicMM-1 (NCT07623798)
- Trial will compare IBI3003 to the investigator’s choice of pomalidomide